Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2/3 1Phase 1/2 1

Status

Terminated 1Recruiting 1Completed 1

Sponsor Class

OTHER 3NIH 3NETWORK 2

Study Type

Interventional 3

Sponsor

Cancer Type

Other hematologic neoplasm 3Myeloid 1Lymphoid 1

Conditions

Recurrence 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Myelodysplastic Syndromes 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid, Acute 1Leukemia 1

Interventions

Cyclophosphamide 2042Radiotherapy 1859Cisplatin 1825Carboplatin 1533Gemcitabine 1434Paclitaxel 1289Bevacizumab 1270Docetaxel 1202pembrolizumab 1198Oxaliplatin 1160Capecitabine 1142Fluorouracil 1061Dexamethasone 971Rituximab 919Nivolumab 908Magnetic Resonance Spectroscopy 862Etoposide 839Doxorubicin 823Drug Therapy 792Radiosurgery 776Irinotecan 775Cytarabine 736fludarabine 716Leucovorin 676Lenalidomide 608fludarabine phosphate 564Temozolomide 552Radiation 541Filgrastim 540Cetuximab 537

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
OTHER × Interventional × Amsacrine × Clear all
NCT03765541 2025-04-10

DEXAML-03

University Hospital, Toulouse

Phase 3 Terminated
73 enrolled
Other hematologic neoplasm

Recurrence, Leukemia, Myeloid, Acute

NCT01228331 2024-12-11

Clofarabine or High-Dose Cytarabine and Pegaspargase in Children with ALL

Universitätsklinikum Hamburg-Eppendorf

Phase 2/3 Completed
745 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT05807932 2024-05-01

Venetoclax in Addition to Sequential Conditioning With Fludarabine / Amsacrine / Ara-C (FLAMSA) + Treosulfan for Allogeneic Blood Stem Cell Transplantation in Patients With MDS, CMML or sAML

Heinrich-Heine University, Duesseldorf

Phase 1/2 Recruiting
38 enrolled
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡